Immupath pooled human plasma enriched with antibodies against HIV data

HEMA reported on patients who have continued to be treated for one year following the end of a Phase I/II clinical trial, announcing that CD4 cells remained stable throughout a 12-month crossover period during which 91 patients chose to receive full-strength Immupath.

The average CD4 level for all patients at start of crossover was 90.7 cells/mm3; at 6 months it was 86.6 cells, and at 12 months it was 89.0 cells. The small number of patients precluded statistical analysis. ...